Beta Bionics projects $131M-$136M 2026 revenue and raises gross margin outlook to 57.5%-59.5% (NASDAQ:BBNX)
Summary
Beta Bionics (BBNX) Q1 2026 earnings call recap: 57% sales growth, higher 2026 guidance, pharmacy mix gains, and FDA risk updates—read now.
Description
Beta Bionics (BBNX) Q1 2026 earnings call recap: 57% sales growth, higher 2026 guidance, pharmacy mix gains, and FDA risk updates—read now.
Original reporting
AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.
Open original source